



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail: hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/14

22nd May, 2026

**Corporate Relationship Department
BSE Limited**
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

**Listing Department
National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

In compliance with Regulation 30 of the Listing Regulations read with SEBI Master Circular dated January 30, 2026, we are pleased to inform you that Gujarat Themis Biosyn Limited (“GTBL”) has entered into definitive agreement for the acquisition of 100% equity shareholding of MicroBiopharm Japan Co., Ltd. (“MBJ”), Japan, through Themis Biosyn Japan Limited, a wholly owned subsidiary of GTBL incorporated in Japan, subject to approvals and customary closing formalities

Name of the Acquirer – Gujarat Themis Biosyn Limited

a)	Name of the target entity, details in brief such as size, turnover etc.;	MicroBiopharm Japan Co., Ltd. (“MBJ”), a Japan based pharmaceutical company engaged in the research, development, and manufacturing of APIs, intermediates, and contract development and manufacturing (CDMO) services. It has established strong capabilities in microbial fermentation and biotechnology based manufacturing and offers a diversified portfolio spanning oncology APIs, plasmid DNA manufacturing, ADC conjugation, and enzyme based bioconversion platforms. MBJ reported estimated revenue of approximately JPY 9.5 Billion (INR 570 Crores) for FY 2026E.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	No. It is not a related party transaction.
c)	Industry to which the entity being acquired belongs;	Pharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	This acquisition represents a significant milestone in GTBL’s long term strategy to evolve from a fermentation led intermediates business into a technology driven Contract Development Manufacturing Organization (CDMO) platform with capabilities across precision fermentation, biotechnology, and next generation drug manufacturing.



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in

e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Subject to obtaining approval under Foreign Exchange and Foreign Trade Act (FEFTA) in Japan and other regulatory approvals.
f)	Indicative time period for completion of the acquisition;	The transaction is expected to close in Q2 FY2027, subject to satisfaction of customary closing conditions and receipt of regulatory approvals.
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Total consideration of JPY 21.5 Billion (approximately INR 1,300 Crores), proposed to be funded through an optimal mix of debt and equity.
h)	Cost of acquisition and/or the price at which the shares are acquired	JPY 21.5 Billion (approximately INR 1,300 Crores).
i)	Percentage of shareholding/control acquired and/or number of shares acquired	Acquisition of 100% equity shareholding of MicroBiopharm Japan Co., Ltd. through Themis Biosyn Japan Limited, a wholly owned subsidiary of GTBL incorporated in Japan.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>MBJ is an established Japanese company with over six decades of experience in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals. The company operates in a compelling platform spanning from manufacturing proprietary pharmaceuticals to CDMO services. It has recorded an estimated revenue of JPY 9.5 billion (approximately INR 570 crores) for FY26</p> <p>Revenues from operations in the last 3 years were: -</p> <p>FY23 – 7,827 Millions (JPY) Approx (INR 470 crores) FY24 – 9,741 Millions (JPY) Approx (INR 580 crores) FY25 – 9,312 Millions (JPY) Approx (INR 560 crores)</p>

The above is for your information and dissemination please.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

Dinesh S. Patel
Chairman & Director
DIN: 00033273